Golden Gate Bridge, San Francisco, CA
Dan Bradbury is a Life Sciences Executive with over 30 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value. He is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm.
Dan is the former President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three firstin-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7 billion in August 2012. Before joining Amylin, Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. He serves as a Director at multiple public and private life sciences companies including Biocon Limited, Castle Biosciences, Equillium Inc, Intercept Pharmaceuticals, Biolinq, IQHQ, DelNova, Liquid Grids, Prosciento, Renova Therapeutics, Sensulin and Synedgen. He also serves on the board of the Riecken Community Libraries, the board of trustees of the Keck Graduate Institute, the BioMed Ventures Advisory Committee, the University of California San Diego’s Rady School of Management's Advisory Council, the board of ADCY5.org, the Pharming Group N.V. Commercial Advisory Board, the ProLynx, LLC Advisory Board, the Arctic Aurora Life Science Advisory Board and is an advisor to Patricia Industries (a part of Investor AB).
Dan received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
During his 20 year tenure at Amylin, Orville Kolterman, M.D. was instrumental in the development of first-in-class diabetes medicines, including SYMLIN, and BYETTA, BYDUREON and Myalept injections. Prior to his appointment as Senior Vice President & Chief Medical Officer, Dr. Kolterman held leadership roles in the regulatory, research, development, clinical and medical affairs departments, many of which were officer-level positions. Before Amylin, he was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the University of California Medical Center. Dr. Kolterman has served as a board member for the American Diabetes Association (ADA) Research Foundation and is a past President of the California Affiliate of the ADA. He has held the role of Adjunct Professor of Medicine at the University of California, San Diego for over 20 years. Dr. Kolterman earned his medical degree from Stanford University School of Medicine. Dr. Kolterman currently serves as the Chief Medical Officer for Pendulum Therapeutics.
Gary T. Elliott brings 35 years in the industry including Vice or Executive Vice President Product Development and Technical Operations with Salmedix, Adventrx, HuyaBioscience, Ribi Immunochem and Sr. Director at Corixa. His experience has been built upon a formal didactive background of Pharmacy, Clinical Pharmacology and Medicinal Chemistry. Dr Elliott has had considerable interaction over the years with US, Canadian and European drug and biologics regulatory authorities, authoring and supervising compilation of many regulatory filings (e.g. INDs, NDAs, annual reports, end of Phase 2, Phase 3 and NDA, CMC, preclinical safety and clinical technical documents) and experience organizing participating and leading associated face to face and telephonic Type A, B and C meetings with regulatory authorities. Dr. Elliott is consequently well versed in preclinical pharmacology, drug safety, CMC, bioanalytical FDA and ICH regulatory guidances and Phase Appropriate Drug Development Strategy as applied in US, EU, Canadian and Australian theatres.
Gary brings integrated technical expertise in formulation, analytical, medicinal chemistry and experience and expertise in Natural Products/plant-derived Drug Substance and Drug Product Development, bioanalytical method development and in vitro and in vivo biological testing. Gary has additionally designed and supervised pharmacology, toxicology and clinical programs in multiple therapeutic areas including but not limited to infectious disease, immunology, oncology and cardiology. Since the successful sale of Salmedix, Gary has served as a consultant to the industry and is currently a Lead consultant and Partner with Pharmaceutical Advisors LLC and President of Galenic Strategies LLC.
Jerry A. Hausman is the MacDonald Professor of Economics at MIT. Professor Hausman received a D.Phil. (Ph.D.) degree from Oxford University where he was a Marshall Scholar. He has been a faculty member at MIT for 45 years. Professor Hausman received the John Bates Clark Award from the American Economics Association in 1985 for the most outstanding contributions to economics by an economist under 40 years of age. He also received the Frisch Medal from the Econometric Society and the Biennial Medal of the Modeling and Simulation Society of Australia and New Zealand. In 2013 he was named a Distinguished Fellow of the American Economic Association. Professor Hausman’s research concentrates on econometrics and applied microeconomics. His applied research has been in demand for differentiated products, telecommunications, regulation, the effects of taxation on the economy, and industrial organization. More information available on his CV.